Epigenetic Regulation in Melanoma: Facts and Hopes

Cells

On Behalf of SCITO YOUTH¹  Vittorio Riccio²  Sara Parola²  Brigitta Mucci²  Emilio Francesco Giunta³  Annalisa Pappalardo³  Gianluca Arrichiello³  Angelica Petrillo³  Anna Diana³  Teresa Fabozzi⁴  Pasqualina Giordano⁴  Piera Federico⁴  Davide Bosso⁴  Margaret Ottaviano⁴  Mario Rosanova⁴  Bruno Daniele⁴  Marcello Curvietto⁵  Vito Vanella⁵  Paolo Antonio Ascierto⁵  Lucia Festino⁵ 

[1] ;Oncology Unit, Department of Clinical Medicine and Surgery, Università degli Studi di Napoli Federico II, 80131 Naples, Italy;Oncology Unit, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, 80131 Naples, Italy;Oncology Unit, Ospedale del Mare, 80147 Naples, Italy;Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80144 Naples, Italy;

关键词: melanoma;    epigenetics;    epigenetic drugs;    DNA methylation;    chromatin remodeling;    non-coding RNA;   

DOI  :  10.3390/cells10082048

来源: DOAJ

【 摘 要 】

Cutaneous melanoma is a lethal disease, even when diagnosed in advanced stages. Although recent progress in biology and treatment has dramatically improved survival rates, new therapeutic approaches are still needed. Deregulation of epigenetics, which mainly controls DNA methylation status and chromatin remodeling, is implied not only in cancer initiation and progression, but also in resistance to antitumor drugs. Epigenetics in melanoma has been studied recently in both melanoma preclinical models and patient samples, highlighting its potential role in different phases of melanomagenesis, as well as in resistance to approved drugs such as immune checkpoint inhibitors and MAPK inhibitors. This review summarizes what is currently known about epigenetics in melanoma and dwells on the recognized and potential new targets for testing epigenetic drugs, alone or together with other agents, in advanced melanoma patients.

【 授权许可】

Unknown